Page 59 - Practice Guidelines News Today

Crystal Denlinger Named Chief Scientific Officer for National Comprehensive Cancer Network PLYMOUTH MEETING, Pa., Jan. 14, 2021 /PRNewswire/ -- The National Comprehensive Cancer Network (NCCN )-an alliance of leading cancer centers-today announced the appointment of Crystal S. Denlinger, MD, FACP, to the newly-created role of Senior Vice President, Chief Scientific Officer. In this position, Dr. Denlinger will help to steer strategic direction for the nonprofit as well as oversee the NCCN Onc...

Share this article PLYMOUTH MEETING, Pa., Jan. 13, 2021 /PRNewswire/ -- New research in the January 2021 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds more than a third of eligible people miss timely screening tests for colorectal cancer and at least a quarter appear to miss timely screening tests for breast and cervical cancers. The study comes from the University of Alberta, Faculty of Medicine and Dentistry in Alberta, Canada, with findings based on self-repo...

Published: Jan 08, 2021   SAN FRANCISCO, Jan. 8, 2021 /PRNewswire/ -- Nearly all cancer patients face fear, anxiety, and uncertainty following diagnosis and treatment. Cancer-related distress can impact a patients emotional and physical well-being, which for many has been further compounded by the COVID-19 pandemic. Founded by a team of biotech veterans, Blue Note Therapeutics, Inc., is leveraging deep scientific and clinical expertise, neuroscience, and digital innovation to make mental h...

12/29/20 WorkersCompensation.com Oakland, CA (WorkersCompensation.com) - The Division of Workers Compensation (DWC) has issued an order updating the Medical Treatment Utilization Schedule (MTUS) Drug List effective February 1, 2021, pursuant to Labor Code section 5307.29. The Administrative Directors update order adopts changes to the MTUS Drug List based on the American College of Occupational and Environmental Medicine (ACOEM) Practice Guidelines, published by Reed Group, Ltd., including the...

ABBVie announced today that the U.S. Food and Drug Administration approved the update of the IMBRUVICA ® Prescribing Information to include efficacy and safety data for the combination of IMBRUVICA with rituximab for the treatment of Waldenström’s macroglobulinemia based on the final analysis of the Phase 3 iNNOVATE study. First approved in 2013, IMBRUVICA is currently available to patients with several types of … – ABBVie (NYSE: ABBV) announced today that the U.S. Food and Drug Admini...

Brief clinical appointments are making it impossible for women with breast cancer to get vital information about issues like whether to have a mastectomy or not, a researcher says. A researcher says informed consent on surgical procedures like a mastectomy may be illusory due to lack of meaningful consultation. Photo: 123RF The claim, by a doctorate researcher in Taranaki, adds to the controversy around informed consent, and whether the principle is being applied meaningfully and legally in th...

utologous anti CD19 transduced CD3+ cells Granted Conditional European Marketing Authorisation for Relapsed and Refractory Mantle Cell Lymphoma --   London, UK – 16 December 2020 – Kite, a Gilead Company, today announced that the European Commission has granted conditional marketing authorisation for its autologous anti CD19 transduced CD3+ cells, a chimeric antigen receptor (CAR) T cell therapy, as a treatment for adult patients with relapsed or refractory mantle cell lymphoma after two ...

F. Hoffmann-La Roche Ltd Roche launches cobas PIK3CA Mutation Test for patients with advanced or metastatic breast cancer in countries accepting the CE mark Roche launches cobas PIK3CA Mutation Test for patients with advanced or metastatic breast cancer in countries accepting the CE mark This genetic test identifies mutations in the PIK3CA gene that can cause cells to grow uncontrollably, which may lead to cancer PIK3CA is the most commonly mutated gene in advanced or metastatic breast cancer,...

Share: This genetic test identifies mutations in the PIK3CA gene that can cause cells to grow uncontrollably, which may lead to cancer PIK3CA is the most commonly mutated gene in advanced or metastatic breast cancer, with nearly 40 percent of patients harbouring a mutation in this gene 1 The cobas PIK3CA Mutation Test is a PCR-based test that detects PIK3CA mutations in patients with metastatic breast cancer to help identify those most likely to benefit from approved therapy 2 Basel, 15 Decemb...

(2) This genetic test identifies mutations in the PIK3CA gene that can cause cells to grow uncontrollably, which may lead to cancer PIK3CA is the most commonly mutated gene in advanced or metastatic breast cancer, with nearly 40 percent of patients harbouring a mutation in this gene 1 The cobas PIK3CA Mutation Test is a PCR-based test that detects PIK3CA mutations in patients with metastatic breast cancer to help identify those most likely to benefit from approved therapy 2 Basel, 15 December ...